3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Lymphoma, Follicular
5
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Advanced Solid Tumors
1
Interventions
10-propargyl-10-deazaaminopterin
12
Cyclophosphamide
8
Prednisone
7
belinostat
6
Vincristine
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Doxorubicin
6
Brentuximab Vedotin
5
romidepsin
4
mogamulizumab
4
darinaparsin
4
Vitamin B 12
4
Gemcitabine
4
Folic Acid
4
selinexor
3
denileukin diftitox
3
Nivolumab
3
Injections
3
Bendamustine Hydrochloride
3
tislelizumab
2
tipifarnib
2
tenalisib
2
duvelisib
2
Rituximab
2
Lenalidomide
2
HBI-8000
2
Fenretinide
2
E7777 fusion protein
2
AFM13
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Peripheral
×
duvelisib
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled
NCT03372057
2025-03-07
PRIMO
SecuraBio
Phase 2
Completed
156 enrolled
21 charts